<?xml version="1.0" encoding="utf-8" ?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>Latest Headlines</title><link>http://htscreening.net/index.aspx</link><description></description><language>en-us</language><lastBuildDate>Tuesday, January 06, 2009</lastBuildDate><copyright>Copyright: (C) Technology Networks Ltd</copyright><item><title>PPD Enters into Strategic Collaboration with Merck</title><description>PPD acquires Merck’s vaccine testing lab and expands existing central lab service relationship.</description><link>http://htscreening.net/index.aspx?ID=97349</link><link1>http://htscreening.net/r/redirect.aspx?contentID=97349&amp;url=http://www.ppdi.com</link1><pubDate>06 January 2009</pubDate></item><item><title>Researchers Advance Knowledge of Little ‘Nano-Machines’ in Our Body</title><description>A discovery by Canada-U.S. biophysicists improves the understanding of ion channels, akin to little ‘nano-machines’ or ‘nano-valves’ in our body.</description><link>http://htscreening.net/index.aspx?ID=97169</link><link1>http://htscreening.net/r/redirect.aspx?contentID=97169&amp;url=http://www.umontreal.ca/</link1><pubDate>22 December 2008</pubDate></item><item><title>VistaGen and WARF Sign License Agreement for Human Embryonic Stem Cell Technology</title><description>The license is expected to accelerate Vistagen’s commercial programs focused on stem cell-based ‘clinical trials in a Test Tube™.</description><link>http://htscreening.net/index.aspx?ID=97119</link><link1>http://htscreening.net/r/redirect.aspx?contentID=97119&amp;url=http://www.vistagen.com/</link1><pubDate>19 December 2008</pubDate></item><item><title>Horizon Discovery Sign Screening Agreement with Actelion Pharmaceuticals</title><description>The agreement covers the screening of a number of Actelion lead compounds on a wide panel of genotypes using Horizon’s X-MAN cell-line technology.</description><link>http://htscreening.net/index.aspx?ID=97072</link><link1>http://htscreening.net/r/redirect.aspx?contentID=97072&amp;url=http://www.horizondiscovery.com</link1><pubDate>18 December 2008</pubDate></item><item><title>Yissum Subsidiary Jexys Announces Research and Development Collaboration Agreement with Teva</title><description>Teva to finance Jexys' R&amp;D program for the development of a high throughput drug discovery platform and in return will receive a minority equity interest in Jexys.</description><link>http://htscreening.net/index.aspx?ID=97027</link><link1>http://htscreening.net/r/redirect.aspx?contentID=97027&amp;url=http://www.yissum.co.il</link1><pubDate>17 December 2008</pubDate></item><item><title>MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program</title><description>MorphoSys and Centocor have enrolled a patient in a Phase 2 clinical trial with a HuCAL-derived fully human antibody.</description><link>http://htscreening.net/index.aspx?ID=96910</link><link1>http://htscreening.net/r/redirect.aspx?contentID=96910&amp;url=http://www.morphosys.com/</link1><pubDate>12 December 2008</pubDate></item></channel></rss>